Time to Reconsider Aceto Corporation (NASDAQ:ACET) After More Short Sellers?

Investors sentiment decreased to 0.28 in 2019 Q1. Its down 0.12, from 0.4 in 2018Q4. It fall, as 20 investors sold Aceto Corporation shares while 12 reduced holdings. 5 funds opened positions while 4 raised stakes. 2.60 million shares or 75.96% less from 10.82 million shares in 2018Q4 were reported.
Royal State Bank Of Canada owns 270 shares. Fmr Ltd Liability holds 601 shares or 0% of its portfolio. Bnp Paribas Arbitrage Sa, a New York-based fund reported 747 shares. Highlander Capital Mgmt Lc reported 0% in Aceto Corporation (NASDAQ:ACET). 247,225 are held by Invesco. Glenmede Tru Na owns 164 shares. Fincl Bank Of America De, North Carolina-based fund reported 17 shares. Citadel Advisors Ltd Liability holds 78,979 shares. Signaturefd Ltd accumulated 315 shares. D E Shaw And holds 0% or 41,369 shares in its portfolio. Blackrock holds 95,068 shares. Spark Limited Liability Company has 55,449 shares for 0% of their portfolio. 42,881 were accumulated by Kbc Grp Nv. Dimensional Fund Advisors Lp holds 0% in Aceto Corporation (NASDAQ:ACET) or 920,837 shares. New York-based Morgan Stanley has invested 0% in Aceto Corporation (NASDAQ:ACET).

The stock of Aceto Corporation (NASDAQ:ACET) registered an increase of 123.61% in short interest. ACET’s total short interest was 742,600 shares in July as published by FINRA. Its up 123.61% from 332,100 shares, reported previously. With 558,800 shares average volume, it will take short sellers 1 days to cover their ACET’s short positions. The short interest to Aceto Corporation’s float is 2.61%.

It closed at $0.1345 lastly. It is up 0.00% since July 14, 2018 and is . It has underperformed by 4.43% the S&P500.

Aceto Corporation, together with its subsidiaries, sources, markets, sells, and distributes finished dosage form generics, nutraceutical products, pharmaceutical intermediates and active ingredients, agricultural protection products, and specialty chemicals. The company has market cap of $. The firm operates in three divisions: Human Health, Pharmaceutical Ingredients, and Performance Chemicals. It currently has negative earnings. The Human Health segment supplies raw materials used in the production of nutritional and packaged dietary supplements, including vitamins, amino acids, iron compounds, and bio chemicals used in pharmaceutical and nutritional preparations.

More notable recent Aceto Corporation (NASDAQ:ACET) news were published by: Globenewswire.com which released: “ACETO to Acquire Generic Products and Related Assets of Citron Pharma and Lucid Pharma – GlobeNewswire” on November 02, 2016, also Prnewswire.com with their article: “RM LAW Announces Class Action Lawsuit Against Aceto Corporation – PR Newswire” published on April 27, 2018, Seekingalpha.com published: “The Future For S&P 500 Dividends Through The End Of 2018 – Seeking Alpha” on July 24, 2018. More interesting news about Aceto Corporation (NASDAQ:ACET) were released by: Marketwatch.com and their article: “Stock market ends with losses as tech and consumer staples skid – MarketWatch” published on April 19, 2018 as well as Globenewswire.com‘s news article titled: “ACETO Appoints Vimal Kavuru to the Board of Directors – GlobeNewswire” with publication date: February 02, 2017.

Aceto Corporation (NASDAQ:ACET) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.